Skip to main content

Advertisement

SpringerLink
Log in

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Background

Neoadjuvant chemotherapy (NAC) has been shown to improve survival in patients with urothelial carcinoma (UC). However, there are a subset of patients who do not respond or progress despite systemic treatment.

Methods

Data from the National Cancer Database on patients who underwent a radical cystectomy (RC) with or without NAC from 2006 to 2013 were abstracted. Covariates were balanced using inverse probability weighting methods. The primary outcome of overall survival in patients with residual disease by stage was evaluated using 90-day conditional landmark analysis and Cox proportional hazards modeling. Secondary outcome of predictors of residual disease was evaluated using multivariable logistic regression analysis.

Results

A total of 20,128 patients met our inclusion criteria; 16,058 patients underwent RC only (80%) and 4070 underwent RC with NAC (20%). Patients who received NAC were younger and healthier, treated at an academic center, and presented with higher stage. NAC was associated with improved overall survival amongst patients with cT3-4aN0 (HR 0.84 95% CI 0.73–0.97; p = 0.02) and cN+ (HR 0.70, 95% CI 0.58–0.86; p = 0.001). Predictors of no residual disease were NAC (OR 0.17, 95% CI 0.14–0.21; p < 0.001) and treatment at an academic facility (OR 0.47, 95% CI 0.37–0.60; p < 0.001). Patients with cT3-4a or cN+ had increased odds of having residual UC (OR 2.01, 95% CI 1.53–2.64; p < 0.001, and OR 2.14, 95% CI 1.43–3.21; p < 0.001, respectively) compared with cT2.

Conclusion

In patients with residual UC, NAC is associated with a significant survival benefit in higher stage disease only. Furthermore, those treated with NAC or at an academic center were less likely to have residual disease. Given the toxicity of NAC, more prudent patient selection for NAC is warranted and requires further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Advanced Bladder Cancer Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205 (discussion 5–6)

    Article  Google Scholar 

  2. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  CAS  Google Scholar 

  3. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S et al (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40–47

    Article  Google Scholar 

  4. Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM et al (2017) Assessing cancer progression and stable disease after neoadjuvant chemotherapy for organ-confined muscle-invasive bladder cancer. Urology 102:148–158

    Article  Google Scholar 

  5. Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3(12):1722–1728

    Article  Google Scholar 

  6. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2007) Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 178:451–454

    Article  Google Scholar 

  7. Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA et al (2014) Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology 83:75–80

    Article  Google Scholar 

  8. Cole SR, Hernan MA (2004) Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75:45–49

    Article  Google Scholar 

  9. Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31:2963–2969

    Article  Google Scholar 

  10. Trialists ICo (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354:533–540

    Article  Google Scholar 

  11. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177

    Article  Google Scholar 

  12. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC et al (2017) Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur Urol 72(5):660–664

    Article  Google Scholar 

  13. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S et al (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61:1229–1238

    Article  Google Scholar 

  14. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65:350–357

    Article  Google Scholar 

  15. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS, Urologic Diseases in America Project (2009) Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer 115:988–996

    Article  Google Scholar 

  16. Seisen T, Jamzadeh A, Leow JJ, Roupret M, Cole AP, Lipsitz SR et al (2017) Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol 4(2):225–229

    Article  Google Scholar 

  17. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165

    Article  CAS  Google Scholar 

  18. Choi W, Ochoa A, McConkey DJ, Aine M, Hoglund M, Kim WY et al (2017) Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol 72:354–365

    Article  CAS  Google Scholar 

  19. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544–554

    Article  CAS  Google Scholar 

  20. Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP et al (2015) Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int 115:230–237

    Article  Google Scholar 

  21. Han KS, Joung JY, Cho KS, Seo HK, Chung J, Park WS et al (2008) Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 22:2699–2704

    Article  Google Scholar 

  22. D’Souza AM, Pohar KS, Arif T, Geyer S, Zynger DL (2012) Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Arch 461:467–474

    Article  CAS  Google Scholar 

  23. Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G et al (2016) Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: does dose intensity matter? Eur J Cancer 54:69–74

    Article  CAS  Google Scholar 

  24. Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z et al (2014) Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU Int 113:36–42

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA

    Izak Faiena, Amirali Salmasi, Neil Mendhiratta, Andrew T. Lenis, Aydin Pooli, Alexandra Drakaki, Allan J. Pantuck & Karim Chamie

  2. Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA

    Izak Faiena, Amirali Salmasi, Aydin Pooli, Alexandra Drakaki, Allan J. Pantuck & Karim Chamie

  3. Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA

    Alexandra Drakaki

  4. Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA

    Kiran Gollapudi & Jeremy Blumberg

  5. 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA

    Izak Faiena

Authors
  1. Izak Faiena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amirali Salmasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil Mendhiratta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew T. Lenis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aydin Pooli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandra Drakaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kiran Gollapudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeremy Blumberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Allan J. Pantuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Karim Chamie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IF: protocol/project development, data collection or management, data analysis, and manuscript writing/editing. AS and KC: protocol/project development, data analysis, and manuscript writing/editing. NM, ATL, and AP: data analysis and manuscript writing/editing. AD: protocol/project development and manuscript writing/editing. KG, JB, and AJP: protocol/project development and manuscript writing/editing.

Corresponding author

Correspondence to Izak Faiena.

Ethics declarations

Conflict of interest

The authors do not report any conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 100 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Faiena, I., Salmasi, A., Mendhiratta, N. et al. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. World J Urol 36, 1825–1833 (2018). https://doi.org/10.1007/s00345-018-2327-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-018-2327-2

Keywords

Search

Navigation